Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

Background and Purpose—This study was designed to evaluate the effectiveness and
safety of rivaroxaban in real-world practice compared with effectiveness and safety of …

Background In a previous systematic review and meta-analysis, we assessed the efficacy
and safety of nonvitamin-K antagonist oral anticoagulants versus warfarin in patients with …

Objective To examine the comparative efficacy and safety of antithrombotic treatments
(apixaban, dabigatran, edoxaban, rivaroxaban and vitamin K antagonists (VKA) at a …

Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone
treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived …

Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral
anticoagulants (DOACs) for patients with atrial fibrillation. Design Systematic review …